Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Autifony Therapeutics Ltd.
DescriptionOral small molecule that modulates potassium channel Kv3.1 (KCNC1)
Molecular Target Potassium channel Kv3.1 (KCNC1)
Mechanism of Action 
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today